Offering includes 100% participation by Akari's Board of Directors, including Akari President and CEO Rachelle JacquesOffering includes accredited investors who have not previously participatedDefinitive
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least 5-fold, improving cost efficiencies in the continuing Phase 3 clinical trial of nomacopan in pediatric
Investegate announcements from Akari Therapeutics Plc, Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
Form 10-K Corbus Pharmaceuticals For: Dec 31 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024Composition of matter patent application filed on long-acting